Physician profile
David Sh Bell
NPI 1730230988
$111,897.17
in general payments reported to CMS, 2019-2025
20 companies · $478 in 2025
The $478 reported for 2025 was less than what a typical Endocrinology, Diabetes & Metabolism provider received nationally (typical 2025 total: $506).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $93K · 2020: $12K · 2021: $4,887 · 2022: $682 · 2023: $654 · 2024: $180 · 2025: $478.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,312.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,311.66 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amarin Pharma, INC. | $46,994.01 | 2019-2020 | |
| Novo Nordisk INC | $25,870.51 | 2019-2023 | |
| Astrazeneca Pharmaceuticals LP | $15,643.01 | 2019 | |
| Janssen Pharmaceuticals, INC | $9,671.58 | 2019 | |
| Bayer Healthcare Pharmaceuticals INC. | $4,976.25 | 2021-2023 | |
| Kowa Pharmaceuticals America, INC. | $3,230.24 | 2019-2021 | |
| Esperion Therapeutics, INC. | $2,480.52 | 2020 | |
| Janssen Scientific Affairs, LLC | $921.17 | 2019-2023 | Xarelto |
| Recordati_rare_diseases_inc. | $344.39 | 2025 | Isturisa |
| Averitas Pharma INC. | $298.43 | 2024-2025 | Qutenza |
| Mannkind Corporation | $294.88 | 2019 | |
| Becton, Dickinson and Company | $283.33 | 2022 | |
| Lilly USA, LLC | $267.10 | 2022-2023 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $222.21 | 2019 | |
| Merck Sharp & Dohme LLC | $134.33 | 2019 |
Show all 20 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $118.56 | 2019 | |
| Corcept Therapeutics | $89.88 | 2019 | |
| Xeris Pharmaceuticals, INC. | $28.44 | 2023 | |
| Lifescan, INC. | $14.78 | 2024 | |
| Boston Scientific Corporation | $13.55 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw David Bell listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.